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RESEARCH ARTICLE
A phase III trial of tirasemtiv as a potential treatment for
amyotrophic lateral sclerosis
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BETTINA M. COCKROFT5, JACQUELINE H. LEE5, FADY I. MALIK5, LISA MENG5,
STACY A. RUDNICKI5, ANDREW A. WOLFF5 &, JINSY A. ANDREWS6 ON BEHALF
OF THE VITALITY-ALS STUDY GROUP
1Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA, 2Department of Neurology,
University of Arizona, Phoenix, AZ, USA, 3Department of Neurology, Neurological Clinical Research Institute,
Massachusetts General Hospital, Boston, MA, USA, 4Academic Unit of Neurology, Trinity Biomedical Sciences
Institute, Trinity College, Dublin, Ireland, 5Cytokinetics, Inc, South San Francisco, CA, USA, and 6The
Neurological Institute, Columbia University, New York, NY, USA
Abstract
Objective: To assess the efficacy of tirasemtiv, a fast skeletal muscle troponin activator, vs. placebo in patients with amyo-
trophic lateral sclerosis. Methods: VITALITY-ALS (NCT02496767) was a multinational, double-blind, randomized, pla-
cebo-controlled clinical trial. Participants tolerating 2 weeks of open-label tirasemtiv (125mg twice daily) were
randomized 3:2:2:2 to placebo or one of three target tirasemtiv dose levels, using an escalating dosage protocol lasting
28 days. The primary outcome measure was changed in slow vital capacity (SVC) at 24 weeks. Secondary endpoints
included a change in muscle strength and time to respiratory milestones of disease progression. Results: Of 744 partici-
pants, 565 tolerated open-label tirasemtiv and received randomized treatment. By 24 weeks, 23 (12.2%) placebo-treated
participants discontinued study treatment vs. 129 (34.2%) randomized to tirasemtiv. SVC declined by 14.4% (95% CI:
16.8, 11.9) in the placebo group and 13.4% (95% CI: 15.3, 11.6) in the tirasemtiv group (p¼ 0.56). Secondary
endpoints did not show significant differences. However, participants who tolerated tirasemtiv at their randomized dose
showed a numeric trend toward a dose-related slowing of decline in SVC (p¼0.11). Dizziness, fatigue, nausea, weight
loss, and insomnia occurred more frequently on tirasemtiv. Serious adverse events were similar across groups.
Conclusions: Tirasemtiv did not alter the decline of SVC or significantly impact secondary outcome measures. Poor toler-
ability of tirasemtiv may have contributed to this result. However, participants tolerating their intended dose exhibited a
trend toward treatment benefit on SVC, suggesting the underlying mechanism of action may still hold promise, as is
being tested with a different fast skeletal muscle troponin activator (NCT03160898).
KEYWORDS: Randomized clinical trial, amyotrophic lateral sclerosis, tirasemtiv
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurode-
generative disorder causing progressive weakness
and death, on average 3–5 years after diagnosis
and most often as a result of respiratory fail-
ure (1–4).
Most therapeutic approaches to treating ALS
have targeted neurodegeneration, although skeletal
muscle is also a plausible target (5). Tirasemtiv, a
fast skeletal muscle troponin activator (FSTA),
increases skeletal muscle contractility by sensitizing
the sarcomere to calcium (6,7).
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A large, multinational, randomized, double-
blind, placebo-controlled, phase IIb clinical trial
(BENEFIT-ALS) (8) randomized 605 participants
with ALS who tolerated 1 week of open-label tira-
semtiv 125mg twice a day (BID). Participants
randomized to tirasemtiv underwent weekly dose
escalation to a maximum tolerated dose of 250mg
BID in the 12-week, double-blind phase of the
study. No treatment effect was noted in the pri-
mary endpoint (change from baseline in ALS
Functional Rating Scale-Revised [ALSFRS-R]).
However, slow vital capacity (SVC) and muscle
strength declined significantly more slowly in tira-
semtiv-treated participants (8). Tirasemtiv reduced
the slope of decline in SVC by 50% during the
12-week treatment phase (9). Dizziness was the
most commonly reported adverse event (AE) (8).
A phase III trial (VITALITY-ALS) was
designed to extend and confirm the findings of
BENEFIT-ALS. Double-blind treatment was
extended to 48 weeks, with the primary outcome,
change in SVC, evaluated at 24 weeks. To
improve tolerability, the open-label period was
extended to 2 weeks, and dose escalation occurred
every 2 weeks rather than weekly. Three target
dose levels were studied.
Methods
Participants
Adults with possible, probable, or definite ALS in
accordance with the revised El Escorial criteria
(10) were enrolled from 79 sites in 11 countries in
North America and Europe. Inclusion criteria
required an upright SVC 70% predicted for age,
height, and sex. No participants were taking edara-
vone during this study, and prior exposure to tira-
semtiv was exclusionary.
Standard protocol approvals, registrations, and
patient consents
All participants in VITALITY-ALS provided written
informed consent, and institutional review board
approvals were received at all sites before enroll-
ment. The study was conducted in accordance with
the Declaration of Helsinki. An independent data
and safety monitoring board monitored safety
throughout the study. This study was registered with
ClinicalTrials.gov (NCT02496767).
Study design
Following a screening period of up to 14 days, eli-
gible participants were enrolled in the trial. The
study included an open-label phase; a 48-week,
double-blind, placebo-controlled phase; and then a
4-week, double-blind, placebo-controlled tirasemtiv
withdrawal phase intended to assess for a potential
rebound effect (none was observed, and not
further discussed here). Participants who success-
fully completed 2 weeks of treatment with open-
label tirasemtiv 125mg BID were randomized
(using a centralized IWRS system) 3:2:2:2 to
matching placebo or one of three different target
daily dose levels of tirasemtiv (250, 375, or
500mg) stratified by riluzole use vs. nonuse. It
was felt that patients who could not tolerate
125mg BID as an initial dose would be unlikely to
complete the study, so we did not titrate to this
dose. All participants on riluzole took 50mg daily
from their personal supply in the morning and a
blinded dose of riluzole in the evening in the same
manner as in BENEFIT-ALS. All participants
randomized to double-blind tirasemtiv continued at
250mg/day (125mg BID) for the first 2 weeks of
double-blind treatment. Participants randomized
to a target daily dosage of 375mg (125mg in the
morning and 250mg in the evening) or 500mg
(250mg BID) of tirasemtiv had their dose adjusted
in 125-mg increments every 2 weeks until the tar-
get dose was reached or signs of intolerance
emerged, in which case the dose was not escalated
or was down-titrated to 250mg daily of tirasemtiv
or matching placebo as necessary due to AEs. This
titration period was not included in the open-label
phase, as differential drop out would have ren-
dered the 3 groups unequal.
The safety analysis set consisted of all partici-
pants who received any dose of study drug.
The full analysis set (FAS) included participants
who received at least one dose of study medication
during the randomized, double-blind, placebo-
controlled phase and had at least one post-
randomization efficacy assessment. There were a
total of six post randomization assessments
through 24 weeks. The per-protocol set (PPS)
consisted of all participants who completed
20 weeks of double-blind, placebo-controlled
treatment, had at least one post-randomization
efficacy assessment on double-blind study treat-
ment, and had no major protocol violations.
Assessments
The last assessment obtained before the first dose
of the open-label phase was considered baseline.
The primary endpoint was change in percent pre-
dicted SVC from baseline to week 24 of the dou-
ble-blind, placebo-controlled phase. Secondary
endpoints included muscle strength assessed by
hand-held dynamometry, the respiratory subscales
of the ALSFRS-R, and time to certain respiratory
milestones of disease progression, such as the initi-
ation of assisted ventilation during the 48 weeks of
randomized, double-blinded treatment. Safety
assessments included physical examinations, clin-
ical laboratory evaluations, vital signs, and moni-
toring of AEs and serious AEs (SAEs).
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Statistical methods
The primary global null hypothesis was that no
treatment difference existed in the change from
baseline in percent predicted SVC at week 24
between participants in the FAS randomized to pla-
cebo and those randomized to tirasemtiv (pooled
three-target dosage levels) during placebo-con-
trolled, double-blind treatment. The original proto-
col sample size estimation indicated that 360
participants were needed to complete the 24 weeks
of double-blind treatment to provide 90% power to
detect a treatment difference from placebo in per-
cent predicted SVC change from baseline to the
end of the first 24-week phase of 6% (an 30%
change from placebo) for all tirasemtiv target dose
groups pooled using a common standard deviation
of 17% with a two-tailed alpha of 0.05. Dropout
rates of 16% at 24 weeks for placebo and 25% for
all tirasemtiv target dose groups combined were
assumed, necessitating 600 participants enrolled
in the study and 477 participants randomized to
placebo and the three different target dose levels of
tirasemtiv in an allocation ratio of 3:2:2:2 in the
double-blind, placebo-controlled treatment phase,
stratifying based on riluzole use. The final sample
size was slightly higher after adjusting for the aggre-
gate blinded standard deviation and dropout rate
during the study. Subjects withdrawing from active
treatment were encouraged to attend all scheduled
study visits and complete assessments and, if unable
to attend, were contacted by phone on a monthly
basis to obtain vital status and respiratory status
through 48 weeks.
The primary analysis was performed using a
repeated-measures mixed model with restricted max-
imum likelihood method (PROC MIXED default;
SASVR , Cary, NC). The model included terms for
treatment, baseline, pooled site, visit, and riluzole
use/nonuse as well as interaction terms for treat-
ment-by-visit and baseline-by-visit with an unstruc-
tured covariance matrix. Multiple imputation by
randomized treatment dosage group was performed
for missing data prior to modeling. The repeated-
measures mixed model was applied to other change
from baseline secondary endpoints. Cox regression
models were used to estimate the hazard ratios of
time to event endpoints between tirasemtiv and pla-
cebo, stratified by randomization strata.
Data availability statement
In collaboration with the ALS association, this
study also included a biofluids collection at every
visit. All demographic and efficacy data will be
migrated to NeuroBANK, a database maintained
by the NEALS Biorepository. Biofluids and pheno-
typic data will be available through application to
the NEALS Biorepository Committee.
Results
Baseline characteristics
Of 866 participants screened, 744 were enrolled
and 565 received randomized treatment (one
patient was randomized but did not receive the
treatment). After successfully completing the open-
label phase, 188 patients received at least one dose
of placebo and 377 received at least one dose of
tirasemtiv. Demographics at study entry (Table 1)
were similar to another recent phase III trials
(8,11–15). The majority of participants (74.5%
[554/744]) were taking riluzole at the start of the
study. Baseline characteristics between riluzole and
non-riluzole strata were similar.
Open-label phase
In the open-label phase of the study, 86.0% (640/
744) of participants experienced AEs, most com-
monly dizziness (48.5% [361/744]), fatigue
(27.4% [204/744]), and nausea (14.5% [108/
744]). Only 1.5% (11/744) of participants (4 not
taking and 7 taking riluzole) experienced SAEs;
23.7% (176/744) of participants discontinued from
the study during the open-label phase, with a simi-
lar discontinuation rate among participants taking
riluzole (26.7% [148/554]) and those not taking
riluzole (31.1% [59/190]) (Figure 1). AEs were
the most common reason for discontinuation, with
11.6% of participants (86/744) discontinuing
because of dizziness, 8.1% (60/744) because of
fatigue, and 4.2% (31/744) because of nausea.
Riluzole did not significantly affect the frequency
or type of AE resulting in discontinuation. The
baseline demographics and disease characteristics
of participants completing the open-label phase
and randomized into the double-blind, placebo-
controlled phase were similar to those at the time
of entry into the open-label phase (Table 1).
Double-blind, placebo-controlled phase
Participant disposition is shown in Figure 1.
Overall, 183 participants were randomized to pla-
cebo; 165 (87.8%) completed 24 weeks of treat-
ment, and 177 (94.1%) completed the week 24
visit. In contrast, 248 (65.8%) participants
randomized to tirasemtiv completed 24 weeks of
treatment and 311 (82.5%) completed the week
24 visit. There were 97 (77.0%), 60 (47.6%), and
39 (31.2%) patients who tolerated and achieved
their randomized target doses of 250mg/day,
375mg/day, and 500mg/day at week 24, respect-
ively. AEs were the most common reason for dis-
continuing therapy and were more common in
participants randomized to tirasemtiv. Termination
from treatment primarily occurred during the first
12 weeks and in relation to dose titration
(Figure 2); the frequency of study drug
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discontinuation was strongly related to the target
dosage level. Down-titrations also occurred early
but were not effective in deterring study drug dis-
continuation. Following 12 weeks of treatment
with the study drug, participants on placebo and
on tirasemtiv stopped treatment at similar rates
(Figure 2). AEs and SAEs are shown in Table 2
and Table 3, respectively; the AE profile was simi-
lar to the previously reported phase II trial. Rates
of SAEs and deaths were not different between
tirasemtiv- and placebo-treated groups. Seventeen
patients died during active treatment on placebo
[9.0%] as compared with 26 deaths during active
treatment on tirasemtiv [6.9%] after >1 year of
exposure to study medication.
At 24 weeks, there was no significant difference
in the decline in percent predicted SVC in the pla-
cebo-treated group compared with all tirasemtiv-
treated participants (14.4% for placebo, 13.4% for
all tirasemtiv; p¼ 0.56). Decline in percent pre-
dicted SVC was 12.6% for the 250-mg target dose
group, 13.7% for the 375-mg target dose group,
and 13.9% for the 500-mg target dose group
(p¼ 0.38, 0.76, and 0.84, respectively). There was
no significant difference between placebo and all
tirasemtiv-treated participants on the following sec-
ondary endpoints: ALSFRS-R respiratory domain
score change from baseline to week 48, slope of
Muscle Strength Mega-Score from baseline to
week 48, time to the first occurrence of a decline
from baseline in percent predicted SVC 20 per-
centage points or the onset of respiratory insuffi-
ciency or death to week 48, time to the first
occurrence of a decline in SVC 50% predicted
or the onset of respiratory insufficiency or death
over 48 weeks, change from baseline in the
ALSFRS-R total score to the end of week 48, and
time to first use of mechanical ventilator assistance
or death to week 48 (p¼ 0.92, 0.75, 0.46, 0.76,
0.61, 0.65, respectively).
To assess whether a potential benefit of tira-
semtiv was masked by poor tolerability, two separ-
ate analyses were performed on more restrictive
data sets. The PPS included participants who
Table 1. Demographics and baseline disease characteristics.
Safety analysis set
Full analysis
set
Parameters
Enrolled
(n5744)
Placebo
(n5 188)
All tirasemtiv
(n5 373) p value
Age, y, mean (SD) 57.6 (10.3) 55.9 (10.6) 56.8 (10.0) 0.29
Age <65 y, n (%) 541 (72.7) 143 (76.1) 291 (78.0) 0.61
Male, n (%) 485 (65.2) 123 (65.4) 263 (70.5) 0.30
Riluzole user, n (%) 554 (74.5) 141 (75.0) 281 (75.3) 0.84
Weight, kg, mean (SD) 79.3 (15.4) 80.7 (15.7) 81.1 (14.8) 0.71
BMI, kg/m2, mean (SD) 26.9 (4.2) 27.3 (4.3) 27.2 (4.1) 0.81
Months from diagnosis, mean (SD) 7.7 (5.8) 8.1 (6.0) 7.4 (5.6) 0.19
Months from first symptom, mean (SD) 20.7 (13.8) 21.5 (16.2) 20.0 (12.9) 0.39
Bulbar onset, n (%) 112 (15.1) 31 (16.5) 54 (14.5) 0.53
ALSFRS-R total score, mean (SD) 38.1 (5.1) 38.3 (5.1) 38.1 (5.3) 0.68
ALSFRS-R respiratory domain score, mean (SD) 11.5 (0.9) 11.6 (0.8) 11.5 (0.9) 0.23
SVC (% predicted), mean (SD) 90.7 (15.7) 90.7 (16.5) 90.4 (15.3) 0.85
ALSFRS-R: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised; BMI: body mass index; SD: standard deviation; SVC:
slow vital capacity.
744
enrolled
179 lead-in 
failures*
188 received 
placebo
377 received
tirasemtiv
129 (34.2%) stopped 
treatment before week 24
• 100 AEs
• 5 deaths 
• 10 progressive disease
• 8 other
• 3 withdrew consent
• 0 protocol deviation
• 1 physician judgment
• 2 lost to follow-up
23 (12.2%) stopped 
treatment before week 24
• 8 AEs
• 3 deaths 
• 5 progressive disease
• 5 other
• 1 withdrew consent
• 0 protocol deviation
• 1 physician judgment
• 0 lost to follow-up
132 (70.2%) 
completed 48 weeks of
double-blind treatment
204 (54.1%) 
completed 48 weeks of
double-blind treatment
44 (17.7%) stopped 
treatment between
weeks 24 & 48
• 9 AEs
• 7 deaths 
• 21 progressive disease
• 3 other
• 3 withdrew consent
• 0 protocol deviation
• 0 physician judgment
• 1 lost to follow-up
33 (20.0%) stopped 
treatment between
weeks 24 & 48
• 5 AEs
• 7 deaths 
• 8 progressive disease
• 4 other
• 3 withdrew consent
• 1 protocol deviation
• 3 physician judgment
• 2 lost to follow-up
566 
randomized*
165 (87.8%) 
completed 24 weeks of
double-blind treatment
248 (65.8%) 
completed 24 weeks of
double-blind treatment
Safety Analysis Set
Figure 1. Patient disposition. One patient was randomized but
did not receive study drug. AE: adverse event.
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completed 20 weeks of study medication and
contributed outcome measures at the 24-week
time point, when the primary outcome measure
was assessed. It eliminated participants who had
stopped study medication for >4 weeks and
includes no imputations for missing data.
However, participants who reduced their dose
were still included within their target dose group.
In this data set, the point estimate of effect was
greater than for the FAS; for the 250-mg target
dosage group in the PPS, percent predicted SVC
declined by 10.0 percentage points, compared
Placebo
250 mg
375 mg
500 mg
Placebo
250 mg
375 mg
500 mg
P
ro
b
ab
ili
ty
 o
f s
ta
yi
ng
 o
n 
as
si
gn
ed
 d
os
e
Weeks on double-blind treatment
Day 1 4 8 12 16 20 24 28 32 36 40 44 48
0.5
0.6
0.7
0.8
0.9
1.0
Log-rank test, placebo vs tirasemtiv: p<0.0001
Censored
Weeks on double-blind treatment
Day 1 4 8 12 16 20 24 28 32 36 40 44 48
0.5
0.6
0.7
0.8
0.9
1.0
Log-rank test, placebo vs tirasemtiv: p<0.0001
Censored
188 186 180 173 171 167 164 158 154 147 145 135 92Placebo
126 115 111 106 102 99 97 94 91 90 88 85 64250 mg
126 106 99 90 85 82 80 78 76 74 73 71 47375 mg
125 108 88 80 75 74 72 71 68 66 65 61 39500 mg
(B)
(A)
Figure 2. Probability of (A) staying on the assigned treatment dose and (B) staying on treatment.
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with 13.1 percentage points for the placebo group
(Table 4). This difference was not statistically sig-
nificant (p¼ 0.13), and there was an inverse dose-
response similar to the primary analysis, with par-
ticipants randomized to higher dosage groups per-
forming less well than the 250-mg target
dosage group.
A second analysis evaluated whether partici-
pants who tolerated their target dose level well
enough to stay at the target dose showed a greater
positive impact of tirasemtiv. Change in SVC was
evaluated as a function of average daily mainten-
ance dosage from the end of week 8 for dose titra-
tion to the end of week 24. In this analysis, all
patients who remained on study drug through
24 weeks were included. The greatest estimate of
effect was noted in participants randomized to the
highest daily dosage (500mg) who were able to
tolerate study drug at that dose (Figure 3).
Participants in this group showed a decline in per-
cent predicted SVC of 9.7 percentage points com-
pared with a drop of 14.2 percentage points in
placebo-treated participants (p¼0.11). This differ-
ence represents a 32% slower decline in SVC for
those treated with tirasemtiv at a daily dosage of
500mg compared with placebo treatment; if this
point estimate was a true effect of tirasemtiv in par-
ticipants who tolerated this dose, such a difference
likely would be clinically important. Every 100mg
of daily tirasemtiv was associated with a
0.19-percentage point (p¼ 0.019) improvement in
change from baseline of percent predicted SVC
per month. This analysis suggested that there was
an expected dose response for those patients who
were able to tolerate tirasemtiv at their assigned
target dosage level, such that participants receiving
lower dosages experienced less of an effect than
those receiving higher dosages of tirasemtiv. No
Table 2. Most common TEAEs during the 48-week, double-blind, placebo-controlled phase.
Preferred term, n (%)
All
participants
(N5 565)
Placebo
(n5 188)
All
tirasemtiv
(n5377)
Difference
(%)
Patients with at least 1 TEAE 557 182 (96.8) 375 (99.5) 2.7
Fatigue 208 61 (32.4) 147 (39.0) 6.6
Dizziness 203 45 (23.9) 158 (41.9) 18
Muscular weakness 186 58 (30.9) 128 (34.0) 3.1
Weight decreased 150 40 (21.3) 110 (29.2) 7.9
Nausea 114 30 (16.0) 84 (22.3) 6.3
Constipation 112 40 (21.3) 72 (19.1) 2.2
Insomnia 103 25 (13.3) 78 (20.7) 7.4
Dysphagia 99 33 (17.6) 66 (17.5) 0.1
Dyspnea 92 35 (18.6) 57 (15.1) 3.5
Muscle spasms 92 34 (18.1) 58 (15.4) 2.7
Contusion 90 34 (18.1) 56 (14.9) 3.2
Nasopharyngitis 81 30 (16.0) 51 (13.5) 2.5
Headache 81 28 (14.9) 53 (14.1) 0.8
Asthenia 78 22 (11.7) 56 (14.9) 3.2
Depression 77 22 (11.7) 55 (14.6) 2.9
Decreased appetite 75 19 (10.1) 56 (14.9) 4.8
Somnolence 70 14 (7.4) 56 (14.9) 7.5
Anxiety 70 19 (10.1) 51 (13.5) 3.4
Skin abrasion 65 24 (12.8) 41 (10.9) 1.9
Posttraumatic pain 64 26 (13.8) 38 (10.1) 3.7
TEAE: treatment-emergent adverse event.
Table 3. Serious AEs occurring in >1% of participants during the 48-week double-blind phase.
Preferred term, n (%)
Placebo
(n5 188)
All tirasemtiv
(n5 377)
Overall
(N5 565)
Patients with serious AEs 53 (28.2) 92 (24.4) 145 (25.7)
Dysphagia 9 (4.79) 21 (5.57) 30 (5.31)
Respiratory failure 8 (4.26) 17 (4.51) 25 (4.42)
Decreased weight 2 (1.06) 10 (2.65) 12 (2.12)
Amyotrophic lateral sclerosis 4 (2.13) 6 (1.59) 10 (1.77)
Pneumonia 4 (2.13) 4 (1.06) 8 (1.42)
Pneumonia aspiration 4 (2.13) 2 (0.53) 6 (1.06)
Traumatic fracture 4 (2.13) 2 (0.53) 6 (1.06)
AE: adverse event.
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treatment effect was observed on ALSFRS-R and
hand-held dynamometry endpoints. When the
baseline characteristics of patients who remained
on double-blind treatment (whether at their target
doses or after down-titration) were compared to
those who did not, those who discontinued dou-
ble-blind treatment were, on average, slightly
older, had lower vital capacities and ALSFRS-R
total scores (and were less likely to be scored as 4
on the dyspnea and orthopnea domains), were less
likely to be on riluzole, and were more likely to
use caffeine.
Discussion
In the primary analysis of the FAS, no significant
differences were seen in the primary outcome
measure or any secondary measures comparing all
tirasemtiv-treated participants with placebo-treated
participants. There appeared to be an inverse
Table 4. Percent predicted SVC change from baseline to week 24 in PPS, mixed model for repeated measures.
Placebo
Tirasemtiv
overall
Tirasemtiv
250mg
Tirasemtiv
375mg
Tirasemtiv
500mg
Patients in PPS, n 157 239 91 79 69
LS means (SE) 13.1 (1.26) 10.9 (1.03) 10.0 (1.64) 10.7 (1.75) 12.4 (1.89)
LS means from placebo (95% CI) 2.2
(0.95, 5.31)
3.1
(0.92, 7.10)
2.4
(1.82, 6.58)
0.8
(3.66, 5.16)
p value 0.1715 0.1310 0.2656 0.7387
CI: confidence interval; LS: least squares; PPS: per-protocol set; SE: standard error; SVC: slow vital capacity.
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dose-response relationship with respect to the pri-
mary outcome measure. However, this is likely
spurious, as many higher-dosage participants had
been reduced to the lowest dose, and more had
also stopped study drug at higher dosages but
remained in the study providing outcome measure
data without receiving therapy.
Results demonstrated that tolerability was not
improved by the dosing strategies used in this
study, indicating that overall tolerability was dose-
dependent and not strongly improved by a slower
dose escalation. A slightly higher percentage of
participants withdrew during the open-label phase
as compared with BENEFIT-ALS. However, of
those who were randomized and continued into
the double-blind phase, approximately the same
percentage of participants stopped study drug by
12 weeks as compared with BENEFIT-ALS by
12 weeks. In both studies, study drug discontinu-
ation occurred early, usually within 1 week of dose
escalation. Dose reductions also occurred early in
VITALITY-ALS but did not improve retention.
Participants who were randomized to higher dos-
ages but were down-titrated to 125mg BID were
much more likely to ultimately stop study drug
than those originally randomized to the same dos-
age. Participants on tirasemtiv also experienced
more AEs, most notably dizziness, fatigue, and
nausea. Importantly, however, there was no
increase in SAE rates in patients on active treat-
ment and no indication of increased mortality.
Despite the impact of poor tolerability on the
results of this study, 2 analyses prespecified in the
protocol suggested a benefit in patients able to tol-
erate tirasemtiv. In the PPS, participants who were
randomized to the 250-mg target daily dose group
of tirasemtiv declined in SVC 24% more slowly
than those on placebo (Table 4). This change, if
true, would be clinically important; the fact that
the difference between active treatment and pla-
cebo was smaller than in BENEFIT-ALS may be
partially explained by the fact that the cohort as a
whole declined more slowly than expected (dis-
cussed below). The observation that the lower dos-
ages were associated with larger treatment
differences was consistent with the inverse dose-
response relationship in tolerability among
randomized dosage groups. However, when partic-
ipants were evaluated according to the mainten-
ance dose from the end of week 8 to the end of
week 24, those who tolerated the highest average
daily dosage (500mg of tirasemtiv daily), showed
an SVC decline that was 32% slower than those
on placebo in the FAS, with a positive dose-
response relationship. Overall, the poor tolerability
of tirasemtiv appears to have masked the potential
treatment benefit with regard to SVC. These
results suggest that the underlying mechanism of
action of tirasemtiv still has promise in patients
with ALS.
This study did not meet its primary endpoint.
Although there was a trend toward benefit in tira-
semtiv-treated participants, it was not statistically
significant and not considered clinically meaning-
ful. There are several reasons why a potential posi-
tive effect was obscured in this study. First, as
discussed above, tolerability was a significant issue,
with >50% more patients stopping study drug on
active treatment as compared with placebo. When
patients who tolerated tirasemtiv were evaluated
separately, much larger and potentially important
estimates of effect were seen. These effects did
not reach statistical significance at least in part
because of the small sample sizes in these groups.
Secondly, participants recruited to this study per-
formed differently than other recent ALS cohorts,
at least with regard to SVC rate of change.
The decline in SVC was lower than expected.
Over 24 weeks, the decline in SVC was 14.2% or
0.080% per day in the placebo group for
VITALITY-ALS. For comparison, the rate of
decline for placebo-treated ALS patients in the
phase III trial of dexpramipexole was 0.088% per
day or 16.9% over 24 weeks and 0.090% per day
for the phase II trial of tirasemtiv. The slower pro-
gression rate in the current study may have con-
tributed to the finding of no significant treatment
effect. However, as was noted in the phase 2 study
(BENEFIT ALS), SVC was the measure that
seemed to show the largest signal among all out-
come measures, confirming that the choice in pri-
mary outcome measure was justified.
Thus, although this phase III study failed to
show a meaningful effect of tirasemtiv on SVC,
subanalyses suggest that tirasemtiv had a biological
effect on SVC, such that fast skeletal muscle
troponin activation remains worthy of further
study. A next-generation FSTA (reldesemtiv), lack-
ing central nervous system effects and having the
potential to produce a larger pharmacodynamic
effect (16), has been reported to show promising
effects in spinal muscular atrophy (17) and is
being tested in a large phase II trial in ALS
patients (NCT03160898).
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